Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
| Autor: | Fangzhou Dou1, Zhenxue Tian2, Xu Yang2, Jing Li1, Ruquan Wang1, Jianjun Gao1 gaojj@qdu.edu.cn |
|---|---|
| Zdroj: | Drug Discoveries & Therapeutics. Dec2022, Vol. 16 Issue 6, p297-299. 3p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|